GERBU Adjuvants – Ready to Use Immunoadjuvants for Better Results
GERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreThe opening of Catalent’s new ultra-modern, commercial-scale plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium was announced on the 26th
Read moreModerna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
Read moreAmerican biotech Oragenics, Inc. announced on Thursday the posting of a preprint manuscript in bioRxiv (pronounced “bio-archives”) evaluating a novel
Read moreThe U.S. Food and Drug Administration (FDA) has approved a second COVID-19 vaccine developed by Moderna, which will be marketed
Read morePfizer and BioNTech announced on Tuesday that a clinical trial in healthy people 18 to 55 years old to assess
Read moreVaccine maker Moderna, which is at the forefront of developing messenger RNA (mRNA) therapeutics and vaccines, announced today that according
Read moreLeading vaccine producers have stated that new vaccines will be developed if necessary to meet the demand of governments worldwide
Read moreA next-generation COVID-19 vaccine, developed by British biotech Emergex, designed to prime T-Cells to rapidly remove viral-infected cells and offer
Read moreThe U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0,
Read more